You are here: Industry Insights > CRISPR

News List

Gene Editing Destiny: The CRISPR Revolution and Beyond Shruti Talashi
August 01, 2024
Genome editing has the potential to eradicate hereditary illnesses, improve human potential, and transform biotechnology and agriculture with continued research and development.
World First: CRISPR Gene Editing Approved in the UK David Orchard-Webb
December 01, 2023
The UK Medicines and Healthcare products Regulatory Agency granted conditional marketing approval for Vertex & CRISPR Therapeutics’ Casgevy to treat Sickle Cell Disease and transfusion-dependent beta thalassemia on November 16, 2023.
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections prnasia
January 11, 2022
SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application...
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog WorldPharmaNews
January 11, 2022
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration...
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting firstwordpharma
August 23, 2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced data on a new gene editing technologytermed SLEEK (SeLection by Essential-gene Exon Knock-in).
Caribou Biosciences Announces Closing of Upsized Initial Public Offering firstwordpharma
July 28, 2021
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the pu
Intellia Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Intellia announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) .
Fox Chase Researcher Receives NIH Grant to Advance Treatment of Immune Diseases Using Genome Editing firstwordpharma
June 29, 2021
A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects.
Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise pharmatimes
June 16, 2021
New data presented at the European Hematology Association 2021 (EHA) virtual congress shows patients treated with Vertex/CRISPR Therapeutics’ blood disorder gene therapy CTX001 had ‘sustained response[s]’ to treatment’.
CRISPR, Capsida team up on gene-edited therapies for ALS, Friedreich's ataxia firstwordpharma
June 16, 2021
CRISPR Therapeutics has inked a partnership with newly launched Capsida Biotherapeutics to develop and commercialise in vivo gene-editing therapies delivered with engineered adeno-associated virus (AAV) vectors for the treatment of familial amyotrophic

Previous page 1 2 3 4 5 6 7 8 Next page